Yu Liao; Qian Zhu; Kexin Sun; Rongshou Zheng; Huihong Deng; Lifeng Lin; Ruilin Meng; Wenqiang Wei; Ye Wang; Yu Liao; Qian Zhu; Kexin Sun; Rongshou Zheng; Huihong Deng; Lifeng Lin; Ruilin Meng; Wenqiang Wei; Ye Wang

doi:10.46234/ccdcw2025.157

[1]

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229 − 63. https://doi.org/10.3322/caac.21834.

[2]

Sun KX, Zheng RS, Lei L, Zhang SW, Zeng HM, Wang SM, et al. Trends in incidence rates, mortality rates, and age-period-cohort effects of cervical cancer - China, 2003-2017. China CDC Wkly 2022;4(48):1070 − 6. https://doi.org/10.46234/ccdcw2022.216.

[3]

Sun KX, Lei L, Zheng RS, Zhang SW, Zeng HM, Wang SM, et al. Trends in incidence rates, mortality rates, and age-period-cohort effects of female breast cancer-China, 2003-2017. China CDC Wkly 2023;5(15):340 − 6. https://doi.org/10.46234/ccdcw2023.065.

[4]

The Department of Maternal and Child Health of the former Ministry of Health. Department of health and national women’s federation notice of issuance of management plan of rural women’s “two cancers” screening program. 2009. https://www.nhc.gov.cn/wjw/gfxwj/200906/e1bed16a6c9b4a07b00389ab9ab202a8.shtml [2025-1-6]. (In Chinese).

[5]

Promotion Committee on Healthy China Initiative. Healthy China action plan (2019-2030). 2019. http://www.gov.cn/xinwen/2019-07/15/content_5409694.htm [2025-1-6]. (In Chinese).

[6]

Guangdong Provincial Center for Disease Control and Prevention. 2021 Guangdong cancer registry annual report. Guangzhou, China: Guangzhou Publishing House Co., LTD; 2024. (In Chinese).

[7]

National Cancer Center. 2021 China cancer registry annual report. Beijing, China: People’s Medical Publishing House Co., LTD. 2023. (In Chinese).

[8]

Sasieni PD, Shelton J, Ormiston-Smith N, Thomson CS, Silcocks PB. What is the lifetime risk of developing cancer?: The effect of adjusting for multiple primaries. Br J Cancer 2011;105(3):460 − 5. https://doi.org/10.1038/bjc.2011.250.

[9]

Zheng RS, Wang SM, Zhang SW, Zeng HM, Chen R, Sun KX, et al. Global, regional, and national lifetime probabilities of developing cancer in 2020. Sci Bull 2023;68(21):2620 − 8. https://doi.org/10.1016/j.scib.2023.09.041.

[10]

Han BF, Zheng RS, Zeng HM, Wang SM, Sun KX, Chen R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent 2024;4(1):47 − 53. https://doi.org/10.1016/j.jncc.2024.01.006.

[11]

Zhu Q, Yao YF, Chen R, Han BF, Wang SM, Li L, et al. Lifetime probabilities of developing and dying from cancer in China: comparison with Japan and the United States in 2022. Sci China Life Sci 2025;68(5):1478 − 86. https://doi.org/10.1007/s11427-024-2810-y.

[12]

Che YH, Geater A, Jing Y, Li L, Zhou SQ, Chongsuvivatwong V, et al. Reproductive variables and risk of breast malignant and benign tumours in Yunnan province, China. Asian Pacific J Cancer Prev 2012;13(5):2179 − 84. https://doi.org/10.7314/apjcp.2012.13.5.2179.

[13]

Chen YJ, Peng Q, Yang Y, Zheng SS, Wang Y, Lu WL. The prevalence and increasing trends of overweight, general obesity, and abdominal obesity among Chinese adults: a repeated cross-sectional study. BMC Public Health 2019;19(1):1293. https://doi.org/10.1186/s12889-019-7633-0.

[14]

Jing LP, Zhong XM, Zhong ZY, Huang WH, Liu Y, Yang G, et al. Prevalence of human papillomavirus infection in Guangdong Province, China: a population-based survey of 78,355 women. Sex Transm Dis 2014;41(12):732 − 8. https://doi.org/10.1097/OLQ.0000000000000201.

[15]

Zhang M, Zhong YJ, Wang LM, et al. Cervical cancer screening coverage-China, 2018-2019. China CDC Wkly 2022;4(48):1077 − 82. https://doi.org/10.46234/ccdcw2022.217.

[16]

Zhang M, Bao HL, Zhang X, Huang ZJ, Zhao ZP, Li C, et al. Breast cancer screening coverage-China, 2018-2019. China CDC Wkly 2023;5(15):321 − 6. https://doi.org/10.46234/ccdcw2023.06.